



NDA 22-575/S-007
NDA 22-575/S-009

SUPPLEMENT APPROVAL

Shire Human Genetic Therapies, Inc.
Attention: Deborah Savuto
Director Regulatory Affairs
300 Shire Way
Lexington, MA 02421

Dear Ms. Savuto:

Please refer to your Supplemental New Drug Applications (sNDA) received October 7, 2011, (S-007) and December 12, 2011, (S-009) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for VPRIV (velaglucerase alfa for injection).

We acknowledge receipt of your amendment to S-007 dated October 3, 2012.

These "Prior Approval" supplemental new drug applications propose the following changes to the package insert:

- Remove reference to the 200 unit vial which as been discontinued
- Add a statement regarding the potential for flocculation in section 2.2 Preparation and Administration Instructions
- Increase the number of geriatric patients treated in section 8.5 Geriatric Use
- Remove a sentence regarding an inadequately validated analytical assay in section 12.3 Pharmacokinetics

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling, with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Heather Buck, Regulatory Project Manager, at (301) 796-1413.

Sincerely,

{See appended electronic signature page}

Joyce Korvick, M.D., M.P.H.
Deputy Director for Safety
Division of Gastroenterology and Inborn Errors Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURE: Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JOYCE A KORVICK
03/26/2013